Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Director Abbie Celniker sold 10,031 shares of the stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $3.00, for a total value of $30,093.00. Following the transaction, the director now directly owns 409,915 shares in the company, valued at approximately $1,229,745. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) opened at 2.80 on Friday. The firm’s 50-day moving average price is $4.23 and its 200-day moving average price is $2.31. The company’s market cap is $43.10 million. Eleven Biotherapeutics Inc. has a 12-month low of $0.25 and a 12-month high of $5.97.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. Eleven Biotherapeutics had a negative return on equity of 207.40% and a negative net margin of 2,995.34%. Analysts expect that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.
Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 7,846 shares during the last quarter. Sabby Management LLC increased its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 1,019,943 shares in the last quarter. Flagship Ventures Fund IV L.P. acquired a new position in Eleven Biotherapeutics during the first quarter worth approximately $469,000. Flagship Ventures Fund 2007 L.P. acquired a new position in Eleven Biotherapeutics during the first quarter worth approximately $610,000. Finally, Boxer Capital LLC acquired a new position in Eleven Biotherapeutics during the second quarter worth approximately $1,670,000. 34.32% of the stock is owned by hedge funds and other institutional investors.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.